Recent advances in therapies for primary myelofibrosis

Recent advances in therapies for primary myelofibrosis

Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling. PMF as well as secondary MF (post-ET and post-PV MF) are the most aggressive...

Bibliografiset tiedot
Päätekijät:	Vainchenker, W, Yahmi, N, Havelange, V, Marty, C, Plo, I, Constantinescu, SN
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Faculty Opinions 2023

Samankaltaisia teoksia

Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]
Tekijä: William Vainchenker, et al.
Julkaistu: (2016-04-01)

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
Tekijä: Lecomte, S, et al.
Julkaistu: (2023)

ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
Tekijä: A. N. Alekseeva, et al.
Julkaistu: (2017-07-01)

Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?
Tekijä: Havelange, V, et al.
Julkaistu: (2023)

Recent developments in myelofibrosis
Tekijä: Mesa RA, et al.
Julkaistu: (2012-07-01)

SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
Tekijä: Willekens, C, et al.
Julkaistu: (2023)

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Tekijä: Timothy Devos, et al.
Julkaistu: (2022-01-01)

Primary myelofibrosis L.
Tekijä: L. M. Meshcheryakova, et al.
Julkaistu: (2014-07-01)

Primary myelofibrosis L.
Tekijä: L. M. Meshcheryakova, et al.
Julkaistu: (2014-07-01)

Primary myelofibrosis in rheumatic diseases
Tekijä: Vladimir Ivanovich Vasilyev, et al.
Julkaistu: (2013-04-01)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [version 1; referees: 2 approved]
Tekijä: William Vainchenker, et al.
Julkaistu: (2018-01-01)

Treatment of primary myelofibrosis
Tekijä: Şinasi Özsoylu
Julkaistu: (2009-12-01)

Editorial: recent advances in molecular and structural endocrinology
Tekijä: De Meyts, P, et al.
Julkaistu: (2023)

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice
Tekijä: Shanti Amé, et al.
Julkaistu: (2023-08-01)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
Tekijä: O. G. Golovina, et al.
Julkaistu: (2024-11-01)

A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
Tekijä: Christen L. Andersen, et al.
Julkaistu: (2014-01-01)

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
Tekijä: Elena Maria Elli, et al.
Julkaistu: (2014-05-01)

Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy
Tekijä: Yasutaka Fukuda, et al.
Julkaistu: (2019-11-01)

Mutational spectrum defines primary and secondary myelofibrosis
Tekijä: Ken I. Mills, et al.
Julkaistu: (2014-01-01)

Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
Tekijä: Miyuki Tsutsui, et al.
Julkaistu: (2019-11-01)

Possibilities of targeted therapy for myelofibrosis: Moscow experience
Tekijä: O. Yu. Vinogradova, et al.
Julkaistu: (2022-11-01)

CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis
Tekijä: Claudio Tripodo, et al.
Julkaistu: (2009-01-01)

Targeted deep sequencing in primary myelofibrosis
Tekijä: Ayalew Tefferi, et al.
Julkaistu: (2016-12-01)

Calreticulin mutations in Chinese with primary myelofibrosis
Tekijä: Bing Li, et al.
Julkaistu: (2014-11-01)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
Tekijä: Marshall A. Lichtman
Julkaistu: (2022-03-01)

Focus on Osteosclerotic Progression in Primary Myelofibrosis
Tekijä: Mariarita Spampinato, et al.
Julkaistu: (2021-01-01)

Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis
Tekijä: Saurabh Kumar, et al.
Julkaistu: (2018-12-01)

Primary myelofibrosis: current therapeutic options
Tekijä: Paula de Melo Campos

Myelofibrosis and Pancytopenia Associated With Primary Hyperparathyroidism
Tekijä: Remya Rajan, MD, et al.
Julkaistu: (2021-01-01)

Does angiogenesis matter in primary myelofibrosis?
Tekijä: Paulo Vidal Campregher
Julkaistu: (2014-10-01)

Patients with primary myelofibrosis: treatment and quality of life
Tekijä: L. M. Meshcheryakova, et al.
Julkaistu: (2014-07-01)

Patients with primary myelofibrosis: treatment and quality of life
Tekijä: L. M. Meshcheryakova, et al.
Julkaistu: (2014-07-01)

Advances in myelofibrosis: a clinical case approach
Tekijä: John O. Mascarenhas, et al.
Julkaistu: (2013-10-01)

Long-term results of splenectomy in primary myelofibrosis
Tekijä: L. M. Meshcheryakova, et al.
Julkaistu: (2014-07-01)

Long-term results of splenectomy in primary myelofibrosis
Tekijä: L. M. Meshcheryakova, et al.
Julkaistu: (2014-07-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
Tekijä: Z. Xu, et al.
Julkaistu: (2022-06-01)

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
Tekijä: Giovanni Barosi, et al.
Julkaistu: (2012-01-01)

Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis
Tekijä: Isabelle Plo, et al.
Julkaistu: (2017-09-01)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
Tekijä: Natalia Korsakova, et al.
Julkaistu: (2023-08-01)

P1015: THE EFFECT OF THERAPY ON THE COAGULATION ACTIVITY OF MICROPARTICLES IN PATIENTS WITH PRIMARY MYELOFIBROSIS
Tekijä: Natalia Silina, et al.
Julkaistu: (2023-08-01)